Hikma and Melinta Therapeutics sign exclusive licensing agreement for two novel anti-infectives for the Middle East and North Africa region

Hikma and Melinta Therapeutics sign exclusive licensing agreement for two novel anti-infectives for the Middle East and North Africa region

London, United Kingdom, (AETOSWire): Hikma Pharmaceuticals PLC (Hikma) and Melinta Therapeutics (Melinta) today announced they have entered into an exclusive licensing agreement for Vabomere® (meropenem and vaborbactam) and Orbactiv® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa (MENA) region. In the United States, Orbactiv® is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections due to designated susceptible Gram-positive pathogens and Vabomere® is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections,…